Compare KMPR & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KMPR | NTLA |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | 7400 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2016 |
| Metric | KMPR | NTLA |
|---|---|---|
| Price | $28.51 | $11.94 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 23 |
| Target Price | ★ $47.67 | $20.02 |
| AVG Volume (30 Days) | 813.2K | ★ 4.2M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,671,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.35 | $62.75 |
| P/E Ratio | $14.38 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $22.69 | $7.95 |
| 52 Week High | $54.90 | $28.24 |
| Indicator | KMPR | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 56.87 | 40.65 |
| Support Level | $29.76 | $10.94 |
| Resistance Level | $30.97 | $15.52 |
| Average True Range (ATR) | 1.16 | 0.58 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 67.92 | 76.16 |
Kemper Corp is an insurance holding company that offers complementary insurance products through its subsidiaries, including personal and commercial automobile insurance to consumers in targeted markets and industries. Kemper also offers life and other insurance solutions based on the needs of its clients. The company offers its insurance products through a vast network of agents and brokers, mainly under the Kemper Auto and Kemper Life brands. It has two operating segments: Specialty Property & Casualty Insurance and Life Insurance. The majority of the company's revenue is generated from the Specialty Property & Casualty Insurance segment, whose principal products are specialty personal automobile and commercial automobile insurance. Geographically, it operates only in the United States.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.